Cholelithiasis in Infants: Risk Factors, Management, and the Role of Ursodeoxycholic Acid
Children · 21.12.2024 · 11 (12) · 1553
DOI: 10.3390/children11121553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Children, online erschienen am 21.12.2024. Verfasst von Sevim Çakar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Gastroenterology, Faculty of Medicine, Dokuz Eylül University, Izmir 35330, Turkey. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cholelithiasis is a rare disease in infants, and there is limited data on its risk factors and management.
Objectives
To evaluate the risk factors, management, and response to medical treatment of cholelithiasis in infants.
Methods
Infants diagnosed with cholelithiasis by ultrasound between 2018 and 2023 were retrospectively analyzed. Details of patient history, imaging findings, current symptoms, and treatments were reviewed.
Results
Over 5 years, 98 infants were diagnosed with cholelithiasis. Thirty-three (33.7%) were girls, and the most common risk factors were the use of cephalosporin antibiotic therapy in 46.9%, sepsis in 30.6%, total parenteral nutrition in 29.6%, prematurity in 27.6%, congenital heart disease in 18.4%, and genetic disease (Down syndrome diagnosis in seven patients) in 16.3%. Only fifteen patients (15.3%) were symptomatic. Ursodeoxycholic acid (UDCA) treatment was given to 90.8% of patients, but nine of them used it for a short period or irregularly, and regular users were 81.6%. Gallstones disappeared in 46 patients (46.9%), including 14 (30.4%) without using UDCA regularly. The response rate to UDCA treatment was lower in preterm infants (p = 0.004). Gallstone resolution was higher in the nonusers, 14/18 (77.8%) versus 32/79 (40.5%) (p = 0.03). Acute cholecystitis was observed in only four patients; no other complications were noted. No infant required surgical or endoscopic treatment.
Conclusions
UDCA should not be used routinely in children, especially infants, except in symptomatic children with a contraindication to surgery or to reduce clinical symptoms. In the absence of symptoms, patients may be monitored clinically.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Gastroenterology, Faculty of Medicine, Dokuz Eylül University, Izmir 35330, Turkey.
- Department of Pediatrics, Division of Pediatric Gastroenterology, University of Health Sciences Dr. Behçet Uz Children's Hospital, Izmir 35210, Turkey.
- Department of Pediatrics, Faculty of Medicine, Ege University, Izmir 35040, Turkey.
Zitieren
APA
Çakar, S., Eren, G., Erdur, C. B., Önder, M., Pelek, Ş., Alpdoğan, S., Demirtaş, D., Ecevit, Ç. Ö., & Bekem, Ö. (2024). Cholelithiasis in Infants: Risk Factors, Management, and the Role of Ursodeoxycholic Acid. Children, 11(12), 1553. https://doi.org/10.3390/children11121553
Vancouver
Çakar S, Eren G, Erdur CB, Önder M, Pelek Ş, Alpdoğan S, et al. Cholelithiasis in Infants: Risk Factors, Management, and the Role of Ursodeoxycholic Acid. Children. 2024;11(12):1553. doi:10.3390/children11121553
BibTeX
@article{akar2024,
author = {Çakar, Sevim and Eren, Gülin and Erdur, Cahit Barış and Önder, Mehmet and Pelek, Şafak and Alpdoğan, Sedef and Demirtaş, Duygu and Ecevit, Çiğdem Ömür and Bekem, Özlem},
title = {Cholelithiasis in Infants: Risk Factors, Management, and the Role of Ursodeoxycholic Acid},
journal = {Children},
year = {2024},
volume = {11},
number = {12},
pages = {1553},
doi = {10.3390/children11121553}
}
EUVIMED